Johnson Pharmacare (532154) Q2 24/25 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter and half year ended September 30, 2024 at the meeting held on November 13, 2024.

• Statutory auditors conducted a limited review and found no material misstatements in the financial statements.

Financial highlights

• Reported a net loss of ₹0.08 lakh for Q2 FY25, compared to a net loss of ₹0.18 lakh in Q2 FY24.

• Net loss for the half year ended September 30, 2024 was ₹4.07 lakh, compared to ₹18.96 lakh for the same period last year.

• Total income from operations was negligible for both the quarter and half year.

• Basic and diluted EPS for the quarter and half year were both ₹(0.00).

Key financial ratios and metrics

• Paid-up equity share capital stood at ₹5,500 lakh as of September 30, 2024.

• Other equity was ₹171.23 lakh as of September 30, 2024.

• Total assets were ₹5,982.90 lakh as of September 30, 2024.